Advertisement

Topics

Companies Related to "Positive Phase Data Novo Diabetes Drug" [Most Relevant Company Matches] RSS

19:20 EDT 22nd September 2018 | BioPortfolio

Here are the most relevant search results for "Positive Phase Data Novo Diabetes Drug" found in our extensive corporate database of over 50,000 company records.

Showing "Positive Phase Data Novo Diabetes Drug" Companies 1–25 of 6,800+

Relevant

Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Bost...


Phase Forward Incorporated

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Sc...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...


Novo A/S

Novo A/S is fully owned by the Novo Nordisk Foundation and is the holding company of the Novo Group. Novo A/S is a private limited liability company and the majority shareholder in the publicly listed and independently operating companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established to manage the Foundation's funds and to invest actively in other companies. We invest in companies th...

Novo Nordisk, Inc.

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic succ...

National Changing Diabetes Program

The National Changing Diabetes® Program (NCDP) is a multi-faceted initiative that brings together leaders in diabetes and policy to improve the lives of people with diabetes. NCDP strives to create change in the U.S. health care system to provide dramatic improvement in the prevention and care of diabetes. Launched in 2005, NCDP is a program of Novo Nordisk. For more information, please visit ...

Novo Nordisk

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufac...

De Novo Pharmaceuticals Ltd

The volume of structural protein data that will emerge in the next few years will serve as a driver that transforms the pharmaceutical industry. Over the next decade it is predicted that the high-resolution 3-D structure of all proteins that precisely define the biological space of human, pathogenic organisms and plant proteomes will be available. As this flood of data on proteins becomes availabl...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment round in April 2000, followed by a second round of funding of £16.75 million in July 2001. Investors in the first round included Avlar Bioventures, Prelude Technology and Cambridge Research and Innovati...

Glooko

Glooko is the leading diabetes data management platform and is trusted by the world’s leaders in diabetes care. Over 6,000 providers in 27 countries use Glooko’s FDA-cleared, HIPAA-compliant Mobile, Population Health and Clinic Upload applications to improve health outcomes for people with diabetes. Glooko seamlessly syncs with the world’s most ...

Novo Nordisk A/S

Novo A/S, the holding company of the Novo Group, is fully owned by the Novo Nordisk Foundation and was established to manage the Foundation's funds and to invest actively in other companies. What makes Novo A/S different from other holding companies and venture capital firms is its expertise in commercialising science, taking a long-term responsibility and investing solely in sustainable solutions...

VistaGen Therapeutics, Inc

VistaGen Therapeutics is a biopharmaceutical company developing breakthrough drugs for disorders of the Central Nervous System (CNS) and diabetes. Our lead drug candidate AV-101 targets two large CNS markets epilepsy and neuropathic pain. Our key R&D partnership applies our clinically predictive in vitro embryonic stem cell technologies to discover and develop a new generation of drug candidates f...

Phase Forward Europe Limited

Phase Forward Incorporated, the leading provider of clinical informatics for drug development, is dedicated to helping pharmaceutical, biotechnology and medical device companies bring needed drugs and therapies to market faster. The company offers proven solutions in electronic data capture (EDC), clinical data management (CDM), electronic patient diary, and adverse event reporting (AER) as either...

Prosidion Ltd

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Ph...

Protemix Corporation Limited

Protemix is a biopharmaceutical company dedicated to the discovery, development and commercialisation of novel treatments for cardiovascular disease, diabetes mellitus and other metabolic disorders and diseases.Protemix has developed an exciting pipeline of diabetes-related drugs, including one compound, Laszarin™, currently undergoing Phase IIb clinical trials and a number of promising pre-clin...

TransPharma Medical Ltd.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing its proprietary active transdermal drug delivery technology. The company aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through indep...

NOVO Engineering

NOVO engineering (www.NOVOengineering.com) is a leading privately held design engineering firm whose team of world-class engineers has been exceeding clients’ needs since 1997. Since its inception NOVO has been helping companies to generate paradigm-shifting new products, commercialize new technology, overcome resource constraints, provide specific te...

NOVO 1

Since 1987, NOVO 1 has been dedicated to tailoring contact center solutions to support clients’ business goals in building customer relationships and growing their brands. NOVO 1′s Customer Obsession Program™ and Smart Desktop Solutions™ incorporate game-changing technology and top 1% industry best-practices to design customized solutio...

Glooko, Inc.

Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Our self-management mobile app automatically syncs data from devices including blood glucose meters, insulin pumps, CGMs, smart insulin pens and many fitness and activity trackers. The broad variet...

Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.

POXEL S.A.

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, ...

Zucara Therapeutics

Zucara Therapeutics, a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in ...

LMC Diabetes & Endocrinology

LMC is an industry leader, providing Phase I-IV clinical trial services in 13 sites with 35 Endocrinologists, across four Canadian provinces. LMC Research is part of the LMC group of multi-disciplinary regional Centres of Excellence aimed at providing complete care in Diabetes, Endocrinology and Metabolism. Specific areas of interest in research primarily ...

Metabolex Incorporated

Metabolex discovers and develops new drugs for type 2 diabetes, bringing to the market novel drugs that address the molecular mechanisms underlying the disease. Such therapeutics are needed to more effectively control patients' blood glucose levels and impede progression of diabetes and its complications.Metabolex has a team of dedicated experts and a robust technology base in diabetes biology and...

DOV Pharmaceutical

We are a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system, cardiovascular and urological disorders. We have five product candidates in clinical trials addressing therapeutic indications with significant unmet needs. Our product candidate for insomnia is currently in Phase III clinical trials and o...


More From BioPortfolio on "Positive Phase Data Novo Diabetes Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks